I agree LeeKing, these are possible reasons but the reality is...

I agree LeeKing, these are possible reasons but the reality is that the market is still punishing companies that have no cash flow and or future sales. The current market cap of $38mil is probably appropriate given the status of the company with only potential FDA approval.Once FDA approval comes in, a market cap of around $100mil is more justified and we should see it lift from there when even the slightest of good cash flow news comes through.

While sales of devices would be a high objective, it is the reoccurring revenue from any medicare rebate that I think the market will appreciate more and the then Nasdaq listing.I have no doubt CDX is a long term winner, and probably a high eventual takeover target, but we just need some more clarification on why the delay for FDA clearance. Suspect it will be a hot topic at the AGM next week.